Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QL325
- Development stage
- Unknown
- Lead developer
- QLSF Biotherapeutics
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
QL325 is a bispecific T-cell engager (TCE) antibody developed by QLSF Biotherapeutics for the treatment of acute myeloid leukemia (AML). The drug is designed to simultaneously target CLEC12A (C-type lectin domain family 12 member A, also known as CLL-1) on leukemic cells and CD3 on T cells. By bridging these two cell types, QL325 redirects T-cell-mediated cytotoxicity to specifically eliminate AML blasts and leukemic stem cells while sparing normal hematopoietic stem cells that lack CLEC12A expression. QLSF Biotherapeutics, a clinical-stage biotechnology company based in South San Francisco, California, has published preclinical research on QL325 in the journal Frontiers in Drug Discovery. The drug is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and preliminary efficacy in patients with hematological malignancies.
02
Targets
CD3 (T-cell surface glycoprotein CD3)CLEC12A
Beyond the preview
Go deeper on QL325.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QL325.